Erikka Loftfield1, Neal D Freedman2, Barry I Graubard2, Albert R Hollenbeck2, Fatma M Shebl2, Susan T Mayne2, Rashmi Sinha2. 1. Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM). erikka.loftfield@nih.gov. 2. Yale School of Public Health, New Haven, CT (EL, FMS, STM); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD (EL, NDF, BIG, RS); AARP (retired), Washington, D.C. (ARH); Yale Cancer Center, New Haven, CT (FMS, STM).
Abstract
BACKGROUND: Cutaneous melanoma is the fifth most common cancer in the United States. Modifiable risk factors, with the exception of exposure to ultraviolet radiation (UVR), are poorly understood. Coffee contains numerous bioactive compounds and may be associated inversely with melanoma. However, previous epidemiological evidence is limited. METHODS: Coffee intake was assessed at baseline with a food frequency questionnaire in the National Institutes of Health-AARP prospective cohort study. Among 447 357 non-Hispanic whites who were cancer-free at baseline, 2904 incident cases of malignant melanoma were identified during 4 329 044 person-years of follow-up, with a median of 10.5 years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee intake and subsequent melanoma risk with non-coffee drinkers as the reference group. Statistical tests were two-sided, and P values less than .05 were interpreted as statistically significant. RESULTS: The highest category of coffee intake was inversely associated with malignant melanoma (≥4 cups/day: HR = 0.80, 95% CI = 0.68 to 0.93, P trend = .01). This association was statistically significant for caffeinated (≥4 cups/day: HR = 0.75, 95% CI = 0.64 to 0.89, P trend = .01) but not for decaffeinated coffee (P trend = .55). CONCLUSIONS: Higher coffee intake was associated with a modest decrease in risk of melanoma in this large US cohort study. Additional investigations of coffee intake and its constituents, particularly caffeine, with melanoma are warranted. Published by Oxford University Press 2015.
BACKGROUND:Cutaneous melanoma is the fifth most common cancer in the United States. Modifiable risk factors, with the exception of exposure to ultraviolet radiation (UVR), are poorly understood. Coffee contains numerous bioactive compounds and may be associated inversely with melanoma. However, previous epidemiological evidence is limited. METHODS: Coffee intake was assessed at baseline with a food frequency questionnaire in the National Institutes of Health-AARP prospective cohort study. Among 447 357 non-Hispanic whites who were cancer-free at baseline, 2904 incident cases of malignant melanoma were identified during 4 329 044 person-years of follow-up, with a median of 10.5 years of follow-up. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee intake and subsequent melanoma risk with non-coffee drinkers as the reference group. Statistical tests were two-sided, and P values less than .05 were interpreted as statistically significant. RESULTS: The highest category of coffee intake was inversely associated with malignant melanoma (≥4 cups/day: HR = 0.80, 95% CI = 0.68 to 0.93, P trend = .01). This association was statistically significant for caffeinated (≥4 cups/day: HR = 0.75, 95% CI = 0.64 to 0.89, P trend = .01) but not for decaffeinated coffee (P trend = .55). CONCLUSIONS: Higher coffee intake was associated with a modest decrease in risk of melanoma in this large US cohort study. Additional investigations of coffee intake and its constituents, particularly caffeine, with melanoma are warranted. Published by Oxford University Press 2015.
Authors: Robert Dubrow; Amy S Darefsky; Neal D Freedman; Albert R Hollenbeck; Rashmi Sinha Journal: Cancer Causes Control Date: 2012-03-29 Impact factor: 2.506
Authors: A-C Goulet; Janine G Einsphar; David S Alberts; Anthony Beas; Cynthia Burk; Achyut Bhattacharyya; Jerry Bangert; Janet M Harmon; Hideji Fujiwara; Alane Koki; Mark A Nelson Journal: Cancer Biol Ther Date: 2003 Nov-Dec Impact factor: 4.742
Authors: Saverio Caini; Giovanna Masala; Calogero Saieva; Marina Kvaskoff; Isabelle Savoye; Carlotta Sacerdote; Oskar Hemmingsson; Bodil Hammer Bech; Kim Overvad; Anne Tjønneland; Kristina E N Petersen; Francesca Romana Mancini; Marie-Christine Boutron-Ruault; Iris Cervenka; Rudolf Kaaks; Tilman Kühn; Heiner Boeing; Anna Floegel; Antonia Trichopoulou; Elisavet Valanou; Maria Kritikou; Giovanna Tagliabue; Salvatore Panico; Rosario Tumino; H B As Bueno-de-Mesquita; Petra H Peeters; Marit B Veierød; Reza Ghiasvand; Marko Lukic; José Ramón Quirós; Maria-Dolores Chirlaque; Eva Ardanaz; Elena Salamanca Fernández; Nerea Larrañaga; Raul Zamora-Ros; Lena Maria Nilsson; Ingrid Ljuslinder; Karin Jirström; Emily Sonestedt; Timothy J Key; Nick Wareham; Kay-Tee Khaw; Marc Gunter; Inge Huybrechts; Neil Murphy; Konstantinos K Tsilidis; Elisabete Weiderpass; Domenico Palli Journal: Int J Cancer Date: 2017-03-09 Impact factor: 7.396
Authors: Melissa M Melough; Shaowei Wu; Wen-Qing Li; Charles Eaton; Hongmei Nan; Linda Snetselaar; Robert Wallace; Abrar A Qureshi; Ock K Chun; Eunyoung Cho Journal: Nutr Cancer Date: 2019-07-23 Impact factor: 2.900
Authors: Kristin A Guertin; Neal D Freedman; Erikka Loftfield; Barry I Graubard; Neil E Caporaso; Rashmi Sinha Journal: Int J Epidemiol Date: 2015-06-16 Impact factor: 7.196